Werbung
Werbung

CSTL

CSTL logo

Castle Biosciences, Inc. Common Stock

39.34
USD
Gesponsert
-0.55
-1.38%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

39.36

+0.02
+0.05%

CSTL Ergebnisberichte

Positives Überraschungsverhältnis

CSTL übertreffen die 20 der letzten 26Schätzungen.

77%

Nächster Bericht

Datum des nächsten Berichts
25. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$77.23M
/
-$0.35
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-7.00%
/
+1650.00%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-10.52%
/
-206.06%

Castle Biosciences, Inc. Common Stock earnings per share and revenue

On 03. Nov. 2025, CSTL reported earnings of -0.02 USD per share (EPS) for Q3 25, beating the estimate of -0.53 USD, resulting in a 96.25% surprise. Revenue reached 83.04 million, compared to an expected 72.63 million, with a 14.33% difference. The market reacted with a +21.70% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.35 USD, with revenue projected to reach 77.23 million USD, implying an increase of 1650.00% EPS, and decrease of -7.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Castle Biosciences, Inc. Common Stock reported EPS of -$0.02, beating estimates by 96.25%, and revenue of $83.04M, 14.33% above expectations.
The stock price moved up 21.7%, changed from $25.99 before the earnings release to $31.63 the day after.
The next earning report is scheduled for 25. Feb. 2026.
Based on 10 analysts, Castle Biosciences, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of $77.23M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung